Low-dose naltrexone, usually shortened to LDN, has moved from a niche topic in integrative medicine into wider conversation. Researchers are studying how it interacts with immune signaling, inflammation, and the body’s natural endorphin pathways, and many patients ask their providers whether it might fit their health goals.
Research is still developing, and LDN is used off-label. Here is what it is, what is known, what is still being studied, and what to discuss with a provider.
What is low-dose naltrexone?
Naltrexone was approved in the 1980s, at standard doses of 50 mg or more, to treat opioid and alcohol dependence. At those doses it blocks opioid receptors in the brain.
Low-dose naltrexone is a much smaller dose, typically compounded by a pharmacy. Researchers believe that at low doses it blocks opioid receptors only briefly, and that the body may respond by increasing production of natural endorphins and enkephalins. These molecules play roles in:
- Mood regulation
- Immune signaling
- Pain modulation
- Nervous system balance
This mechanism is why LDN has drawn interest across several areas of medicine.
How does low-dose naltrexone work?
LDN is thought to influence the immune system and inflammation rather than directly suppress symptoms. One area of active research is neuroinflammation. Microglia, the immune cells of the brain, can release inflammatory signals when they become overactive. Early research suggests LDN may modulate microglial activity, though this is still being studied and results are not established.
Because the immune system, gut health, metabolism, and nervous system all influence each other, researchers are exploring LDN as part of a broader, whole-system view of health.
What is low-dose naltrexone used for?
LDN is prescribed off-label, which means for uses the FDA has not approved. Providers in functional and integrative medicine most often consider it for conditions involving inflammation or immune signaling, including:
- Fibromyalgia and chronic pain
- Autoimmune conditions
- Persistent fatigue and post-viral conditions such as long COVID
- Neurological sensitivity and brain fog
Some people also ask about LDN in the context of neurodiversity, including ADHD and autism. Research here is early. Some studies and clinical observations suggest possible effects on mood regulation, irritability, and sleep, but responses vary widely, and LDN is not an established treatment for these conditions.
What research still needs to answer
LDN remains an emerging therapy. Large clinical trials are limited, and many studies are exploratory. Open questions include:
- Which conditions benefit most
- Which biological markers predict who responds
- Optimal dosing strategies
- Long-term safety and effectiveness
Because every person’s biology is different, something that helps one person may not help another. That is why personalized medical guidance matters.
Who might consider low-dose naltrexone?
People who ask about LDN are often exploring supportive options for chronic inflammation, persistent fatigue, autoimmune conditions, chronic pain, or neurological sensitivity. LDN is not a one-size-fits-all treatment. Anyone interested should talk with a qualified provider who can review their health history, current medications, and goals.
DrWell’s low-dose naltrexone
Low-dose naltrexone is a compounded, low-dose version of the FDA-approved medication naltrexone. Providers use it off-label to support immune regulation, reduce inflammation, and help manage chronic pain conditions. It is commonly used in functional and integrative medicine for patients with autoimmune disorders, fibromyalgia, long COVID, chronic fatigue, and inflammatory conditions. Compounded LDN is not FDA approved, and treatment is personalized based on your symptoms, health history, and provider guidance.
%20(1)%20(1)%20(1).png)